Alterity Therapeutics Reveals Positive MSA Trial Data
Company Announcements

Alterity Therapeutics Reveals Positive MSA Trial Data

Alterity Therapeutics Ltd. (AU:ATH) has released an update.

Alterity Therapeutics has reported promising interim data from its Phase 2 clinical trials of ATH434, showing potential to modify disease progression in Multiple System Atrophy (MSA). With a cash balance of A$9.28 million, the company remains optimistic as it anticipates releasing topline results in 2025. Additionally, Alterity has strengthened its leadership by appointing Abby Macnish Niven as CFO.

For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlterity Therapeutics reports cash balance of A$9.28M as of September 30
TipRanks Australian Auto-Generated NewsdeskAlterity Therapeutics Prepares for 2024 Annual General Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App